title: Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease.
abstract: REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD). In this study, we assessed the effects of rotigotine transdermal patch on RBD features in patients with PD.
  
  
  
  In this prospective open-label study, eleven PD patients with untreated RBD were administered rotigotine patches for up to seven months to ameliorate their parkinsonism. The severities of their RBD symptoms before and after rotigotine therapy were evaluated through patient and bed partner interviews, a validated evaluation scale (REM sleep behavior disorder questionnaire-Hong Kong, RBDQ-HK), and blinded assessments based on video-polysomnographic (VPSG) measure.
  
  
  
  Rotigotine improved parkinsonism and subjective sleep quality in PD patients with RBD. The RBDQ-HK total score, especially the Factor 2 score, was decreased, which demonstrated that the subjective severity of RBD symptoms was improved after rotigotine treatment, especially the frequency and severity of abnormal RBD-related motor behaviors. The VPSG analyses showed that the total sleep time (TST) and stage 1% were increased and that the PLMS index was decreased. However, no differences in the RBD-related sleep measures were observed.
  
  
  
  The improved RBD symptoms and VPSG measures of PD patients in this study (TST, stage 1%, and PLMS index) suggest that, in PD, rotigotine may partially improve RBD-related symptoms. Rotigotine should be considered to be an optional drug for the treatment of RBD symptoms in PD.
authors: Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors: Yan
authors: Y
authors: Wang
authors: Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors: Yuechang
authors: Y
authors: Yang
authors: Sleep Center, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors: Huijuan
authors: H
authors: Wu
authors: Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors: Danmei
authors: D
authors: Lan
authors: Sleep Center, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors: Ying
authors: Y
authors: Chen
authors: Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
authors: Zhongxin
authors: Z
authors: Zhao
mesh_terms: D000368:Aged; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006723:Hong Kong; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000150:complications*; D017286:Polysomnography; D011446:Prospective Studies; D020187:REM Sleep Behavior Disorder / Q000150:complications* / Q000188:drug therapy*; D012720:Severity of Illness Index; D012895:Sleep, REM / Q000187:drug effects; D011795:Surveys and Questionnaires; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*; D057968:Transdermal Patch; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine
keywords: Parkinson disease; REM sleep behavior disorder; dopamine agonist; rotigotine transdermal patch; video-polysomnography